|
2023-04-07
|
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma
published
| article-journal
doi:10.1200/jco.22.01579
|
|
2023-10-30
|
Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
published
| article-journal
| CC-BY
doi:10.1016/j.ctro.2023.100697
|
|
2024-01-22
|
Clinical and genomic predictors of adverse events in newly diagnosed glioblastoma
published
| article-journal
doi:10.1158/1078-0432.ccr-23-3018
|
|
2023-09-29
|
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
published
| article-journal
doi:10.1200/jco.23.01059
|
|
2024-06-24
|
The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review
published
| article-journal
doi:10.1093/neuonc/noae107
|
|
2024-03-13
|
Burnout and career satisfaction in young neuro-oncology investigators: results of the Society for Neuro-Oncology (SNO) young investigator survey
published
| article-journal
doi:10.1093/nop/npae018
|
|
2024-08-21
|
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors
published
| article-journal
doi:10.1093/neuonc/noae164
|
|
2024-12-19
|
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes
published
| article-journal
doi:10.1093/noajnl/vdae227
|
|
2024-08-05
|
GROWS (<i>Glioma Resource Outreach With Support</i>): A Program to Identify and Initiate Supportive Care Interventions for Unmet Needs Among Adult Lower Grade Glioma Patients
published
| article-journal
doi:10.1093/nop/npae065
|